Summary & Overview
HCPCS S2102: Islet Cell Transplant from Pancreas, Allogeneic
HCPCS Level II code S2102 represents an allogeneic islet cell transplant from the pancreas — a cellular transplant procedure used to restore insulin production in patients with insulin-dependent diabetes. The code captures a highly specialized clinical service that is important nationally due to its role in advanced diabetes management and its implications for transplant program capacity, coverage policy, and high-cost care pathways.
This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how S2102 is defined, typical clinical settings where the service is delivered, and the payer landscape addressed in the publication.
The publication provides benchmarks and policy context relevant to S2102, including common billing and coverage considerations, expected site-of-service patterns (hospital inpatient and specialized transplant centers), and clinical context for islet transplantation. Where payer-specific policies are available, the piece summarizes coverage scope and administrative considerations. Data not available in the input are flagged explicitly in the relevant sections.
Billing Code Overview
HCPCS Level II code S2102 describes islet cell tissue transplant from pancreas; allogeneic. This service involves transplantation of pancreatic islet cells obtained from a donor for the purpose of restoring insulin production in recipients with insulin-dependent diabetes.
-
Service type: Allogeneic islet cell transplant (cellular/tissue transplant procedure)
-
Typical site of service: Hospital inpatient or specialized transplant center (facility settings that support cellular and organ transplantation)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with brittle type 1 diabetes mellitus and frequent severe hypoglycemia episodes is evaluated for an allogeneic islet cell transplant from pancreas. The multidisciplinary workflow includes endocrinology assessment for glycemic control history and transplant candidacy, transplant surgery coordination for procurement and implantation logistics, immunology for pre-transplant crossmatch and HLA considerations, and infectious disease for pre-transplant screening and prophylaxis. Pre-procedure steps include detailed informed consent, metabolic and cardiac clearance, imaging as needed, and placement of vascular access for peri-procedural infusions. On the day of transplantation, donor pancreatic islet cells processed in a certified laboratory are infused into the recipient’s portal vein under interventional radiology guidance. Post-procedure care involves inpatient monitoring for portal hypertension, bleeding, and thrombosis, tight glycemic monitoring with insulin adjustments, initiation and management of immunosuppression, and scheduled follow-up with endocrinology and transplant services for graft function assessment and long-term outcomes tracking.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or risk substantially exceeds typical for islet infusion procedures and documentation supports increased resources. |